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Introduction
Fibrosis is a pathobiological process common to many human 
diseases characterized by the progressive replacement of nor-
mal parenchymal tissue with collagen-rich extracellular matrix 
(Desmoulière  et  al.,  2003).  Fibrogenesis  occurs  through  the   
aberrant accumulation and activation of myofibroblasts, which 
deposit extracellular matrix components and remodel the tissue 
(Kuhn and McDonald, 1991; Zhang et al., 1994), culminating in 
increased tissue mechanical stiffness (Gross and Hunninghake, 
2001; Tomasek et al., 2002). In its most severe clinical manifes-
tations, fibrosis can reach a progressive and self-sustaining phase, 
the cause of which remains largely mysterious.
Much attention has focused on the role that soluble in-
flammatory and fibrogenic mediators play in the initiation and 
progression of fibrosis (Wynn, 2008). However, recent observa-
tions have highlighted the fact that variations in matrix stiffness 
potently alter fibroblast morphology, proliferation, TGF- sig-
naling, and myofibroblast activation (Arora et al., 1999; Wang 
et al., 2000; Paszek et al., 2005; Goffin et al., 2006; Wipff et al., 
2007). These findings raise the intriguing possibility that stiff-
ening of the mechanical environment, long regarded only as an 
outcome of fibrosis, might play a pivotal role in driving the cel-
lular behaviors that promote, amplify, and perpetuate fibrosis. 
In the rat liver, macroscale measurements of organ stiffness dur-
ing onset of carbon tetrachloride–induced fibrosis indicate that 
stiffening occurs rapidly and may even precede measurable 
fibrosis, suggesting a possible role for stiffening in the initial 
stages of fibrosis (Georges et al., 2007). In the lung, fibrotic le-
sions are heterogeneously distributed, and although it is known 
that fibrosis alters gross tissue mechanics (Bachofen and Scherrer, 
1967), measurements of stiffness at the local microscale rel-
evant to resident cells are not available. Thus, the role of matrix 
stiffening in promoting lung fibrogenesis remains untested.
To assess the role that pathophysiological matrix stiffen-
ing plays in the promotion of fibrogenesis, we designed experi-
ments to measure the stiffness of normal and fibrotic lung tissue 
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issue stiffening is a hallmark of fibrotic disorders but 
has traditionally been regarded as an outcome of   
fibrosis, not a contributing factor to pathogenesis.   
In this study, we show that fibrosis induced by bleomycin   
injury in the murine lung locally increases median tissue stiff-
ness sixfold relative to normal lung parenchyma. Across this 
pathophysiological stiffness range, cultured lung fibroblasts 
transition from a surprisingly quiescent state to progressive 
increases in proliferation and matrix synthesis, accompa-
nied by coordinated decreases in matrix proteolytic gene 
expression. Increasing matrix stiffness strongly suppresses 
fibroblast  expression  of  COX-2  (cyclooxygenase-2)  and 
synthesis of prostaglandin E2 (PGE2), an autocrine inhibi-
tor of fibrogenesis. Exogenous PGE2 or an agonist of the 
prostanoid EP2 receptor completely counteracts the prolif-
erative and matrix synthetic effects caused by increased 
stiffness. Together, these results demonstrate a dominant 
role for normal tissue compliance, acting in part through 
autocrine PGE2, in maintaining fibroblast quiescence and 
reveal a feedback relationship between matrix stiffening, 
COX-2 suppression, and fibroblast activation that pro-
motes and amplifies progressive fibrosis.
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in stiffness were restricted to collagen-enriched regions; when 
we examined the tissue stiffness of bleomycin-treated lungs in 
areas devoid of fibrosis, the shear modulus was similar to that 
observed in saline-treated lungs (Fig. S1 C). Together, the elas-
ticity mapping results emphasize the focal nature of stiffness 
changes in early fibrotic lesions and establish an unexpectedly 
large range in tissue stiffness between highly compliant normal 
lung parenchyma and locally stiffened fibrotic lesions.
and investigated key fibrogenic behaviors of human lung fibro-
blasts grown on substrates spanning this stiffness range. Our   
results demonstrate a pivotal role for matrix stiffening in pro-
motion of fibroblast proliferation and matrix synthesis and uncover 
stiffness-driven suppression of COX-2 (cyclooxygenase-2) ex-
pression and PGE2 (prostaglandin E2) synthesis as a key link 
between matrix stiffening and fibroblast activation. We further 
show that PGE2 and Rho kinase (ROCK) exert mutually antago-
nistic effects on fibroblasts, leading to stable and diametrically 
opposed quiescent and activated states influenced by the stiff-
ness of the underlying matrix. Because matrix stiffening pro-
motes  self-reinforcing  effects  on  fibroblast  matrix  synthesis, 
our findings show how feedback signaling in the context of   
mutually antagonistic signaling cascades can switch fibroblasts 
from a quiescent state to self-sustaining activation supportive of 
progressive fibrosis.
Results
Stiffness of normal and fibrotic lung tissue
To establish baseline data on the homogeneity and variance of 
lung parenchymal tissue stiffness at a scale relevant to resident 
cells, we prepared thin slices of fresh murine lung tissue and 
applied atomic force microscopy (AFM) microindentation to 
map local elastic properties (Fig. 1). To compare normal and   
fibrotic tissue stiffness, samples were harvested 14 d after intra-
tracheal administration of either saline or bleomycin. Adminis-
tration of the latter is well recognized to induce pulmonary 
fibrosis in a heterogeneous pattern that mimics aspects of   
human pulmonary fibrosis (Moore and Hogaboam, 2008). Con-
sistent with prior work in mice, bleomycin-treated lungs exhib-
ited focal increases in expression of collagen I (Fig. 1 A) and the 
myofibroblast marker –smooth muscle actin (-SMA; not   
depicted; Zhang et al., 1994; Pena et al., 2007; Moore and   
Hogaboam, 2008). Stiffness mapping was performed in areas 
devoid of major airways or blood vessels (Fig. 1 A); in bleomycin-
treated lungs, mapping was restricted (except where noted) to 
areas of grossly evident fibrosis.
Elastographs from AFM microindentation mapping dem-
onstrated striking differences in the range and distribution of 
tissue stiffness in normal and fibrotic lung parenchyma (Fig. 1 B 
and Fig. S1). The parenchymal tissue from saline-treated lungs 
was highly compliant (median shear modulus 0.5 kPa), with 
only rare portions of the mapping area exhibiting stiffness >3 kPa. 
These observations, the first made on intact lung parenchyma 
at the microscale, are consistent with a long-standing model   
of lung mechanics in which alveolar walls are assumed to   
offer  negligible  contributions  to  lung  elasticity  compared   
with the extracellular matrix–rich connective tissue sheath that 
connects the alveolar ducts, airways, and pleura (Wilson and 
Bachofen, 1982). In bleomycin-treated lungs, regions rich in 
collagen  I  expression  exhibited  an  overall  increase  in  shear 
modulus to a median 3 kPa, with highly localized increases in 
stiffness to >15 kPa (Fig. 1 C and Fig. S1 B). These focal 
changes in tissue stiffness far exceed the two- to threefold in-
creases in stiffness observed previously in tissue strips from 
bleomycin-treated lungs (Ebihara et al., 2000). Local increases 
Figure 1.  Fibrosis focally increases stiffness of lung parenchymal tissue. 
(A) Immunostaining of collagen I in fresh, unfixed saline (left)- and bleo-
mycin (right)-treated mouse lung parenchyma. Bar, 100 µm. (B) Repre-
sentative elastographs of saline (left)- and bleomycin (right)-treated mouse 
lung parenchyma. Maps were made from tissue in the respective regions of 
interest identified in A. The color bar indicates shear modulus. Darkest blue 
corresponds to shear modulus values between 0.05 and 2 kPa. (C) Occur-
rence frequency analysis of stiffness in saline- and bleomycin (Bleo)-treated 
lung tissue. Data indicate mean ± SD of stiffness measurements pooled 
from five animals each for normal and fibrotic groups in two independent 
bleomycin injection experiments. (Inset) Stiffness increases in fibrotic lung 
parenchyma presented as box and whisker plots, in which the vertical line 
within each box represents the median, the limits of each box represent the 
interquartile range, and the whiskers represent the maximum and minimum 
values. *, P < 0.0001 comparing stiffness of fibrotic versus normal lung 
parenchyma using the Mann-Whitney-Wilcoxon test.695 Matrix stiffening amplifies fibrosis • Liu et al.
depletion for 24 h revealed the opposite pattern of staining for 
active caspases 3/7, end effectors of apoptosis (Fig. 2 D and   
Fig. S3 B), with decreased staining observed as substrate stiff-
ness increased. Consistent with stiffness-dependent protection 
from apoptosis, a similar but more muted distribution of active 
caspase 3/7 was observed across the stiffness gradient in the pres-
ence of serum (unpublished data). These results concur with 
and considerably extend prior findings in 2D (Wang et al., 2000) 
and 3D (Fringer and Grinnell, 2001) systems by demonstrating 
that a critical shift in bias from fibroblast apoptosis to prolifera-
tion occurs within the pathophysiological stiffness range mea-
sured in normal and fibrotic lung parenchyma.
Because cells have previously been shown to preferentially 
migrate toward stiffer regions when cultured on substrates with 
sharp stiffness gradients (Lo et al., 2000), we measured lung fibro-
blast migration at various locations along the stiffness gradient. 
Although fibroblast migration speed and persistence varied   
with substrate stiffness (Fig. 2 F), consistent with prior observa-
tions using vascular smooth muscle cells (Peyton and Putnam, 
2005), no preferential migration relative to the direction of the 
stiffness gradient was observed (Fig. 2 G). A similar lack of pref-
erential migration has been observed in vascular smooth muscle 
cells on stiffness gradients of similar slope (Isenberg et al., 2009). 
Although we cannot rule out a role for stiffness-directed migra-
tion in the steeper stiffness gradients found in the intact lung,   
in the current experiments, the predominant factor in stiffness-
  dependent accumulation appeared to be the shift in balance   
between apoptosis and proliferation. Subsequent observations of 
fibroblast accumulation in wells of discrete stiffness, where migra-
tion along a stiffness gradient was not a factor, revealed similar pat-
terns to those observed in the stiffness gradient, which is consistent 
with a dominant role for proliferation over migration (see Matrix 
stiffness promotes fibrogenesis through COX-2 suppression).
Regulation of fibroblast matrix synthesis 
by stiffness
Fibroblasts are the major source for excess deposition of extra-
cellular matrix components, including collagen I, in fibrotic dis-
orders (Hinz et al., 2007). We observed a gradual increase in 
procollagen I immunofluorescence staining in cells along a con-
tinuous stiffness gradient (Fig. 3, A and B; and Fig. S3 C), starting 
from no detectable procollagen I signal at physiological median 
stiffness (0.5 kPa). Analysis of mRNA from fibroblasts grown 
on discrete stiffness gels demonstrated parallel increases in 
COL1A1 and COL3A1 transcripts (encoding collagen I[1] and 
collagen III[1] chains) with increasing stiffness and a prominent 
decrease  in  expression  of  MMP1  (encoding  collagenase-1;   
Fig. 3 C). Although stiffness-mediated expression of collagen gene 
expression has been noted previously (Li et al., 2007), our results 
extend this observation by demonstrating enhanced procollagen 
protein expression and parallel decreases in gene expression of a 
key collagenolytic enzyme with increasing stiffness. Further sup-
porting a matrix synthetic effect of increasing stiffness, we found 
that net secretion of collagen increased on a per cell basis as ma-
trix stiffness increased on discrete stiffness gels (Fig. 3 D).
Supplementation  of  culture  medium  with  exogenous 
TGF-1 for 3 d shifted procollagen I protein expression to as 
Regulation of fibroblast accumulation by 
matrix stiffness
To elucidate the effects of variations in stiffness on lung fibro-
blast biology, we designed and fabricated gradient stiffness hydro-
gel substrates by using photopolymerization of polyacrylamide 
through gradient masks, an approach adapted from Wong et al. 
(2003). The resulting hydrogels exhibited a 1D gradient in shear 
moduli spanning 0.1–50 kPa over a distance of 6 mm (Fig. S2 A).   
The stiffness range was selected to encompass and surpass that 
observed in the murine bleomycin model to account for the in-
creasing stiffness of extensively cross-linked mature fibrotic le-
sions (Dunn et al., 1985). To permit cell attachment, the inert 
polyacrylamide surface was derivatized with collagen I using a 
heterobifunctional cross-linker. The uniformity of the collagen I 
surface density was confirmed by immunostaining with collagen I   
primary antibody, followed by secondary antibody conjugated to 
fluorescently labeled beads that interact only with surface- 
available antigens (Fig. S2; Pelham and Wang, 1997).
Human  lung  fibroblasts  (CCL-151)  attached  uniformly 
across the stiffness gradient, with only modest variability in the 
degree of cell spreading apparent at 4 h (Fig. 2 A). However, in-
cubation of fibroblasts on these stiffness gradients for 120 h in the 
presence of 10% FBS gave rise to striking patterns of stiffness-
dependent fibroblast morphology and accumulation (Fig. 2 A). 
Increasing stiffness was accompanied by prominent transitions in 
fibroblast morphology from attenuated, rounded cells at low stiff-
ness to an appearance marked by multiple dendritic processes at 
intermediate stiffness (Fig. 2 A). At stiffness levels of 20–50 kPa, 
fibroblasts aligned in parallel swirls of spindle-shaped cells typi-
cal of patterns observed in 3D fibroblastic foci in vivo (Kuhn and 
McDonald, 1991; Gross and Hunninghake, 2001) and on stan-
dard rigid cell culture substrates. The crossover from net cell loss 
at low stiffness to cell accumulation at high stiffness identified an 
equilibrium point where cell migration, proliferation, and death 
were in balance under the given culture conditions (Fig. 2 B).   
Intriguingly, we observed this intersection to occur reproducibly 
at shear moduli in the range of 0.5–3 kPa, which is only slightly 
higher than the median shear modulus measured in normal lung 
tissue. The pattern of stiffness-dependent accumulation was at-
tenuated when serum was diluted (Fig. 2 C), indicating that both 
soluble and mechanical factors were necessary elements in the 
response. However, addition of the fibrogenic cytokine TGF-1 
did not alter the pattern of cell accumulation anywhere along the 
stiffness gradient (Fig. 2 C). Together, these results suggest that 
the compliance of the normal lung itself protects against fibro-
blast proliferation, even in the presence of a growth-promoting   
or fibrogenic-soluble environment, but that only relatively small 
changes in stiffness are needed to shift lung fibroblasts into a 
mode of rapid accumulation.
To  elucidate  the  cellular  processes  contributing  to  the 
stiffness-dependent accumulation of fibroblasts, we compared 
cell proliferation, apoptosis, and migration across the stiffness 
gradient. BrdU-positive cells, indicative of ongoing DNA syn-
thesis, were absent from areas of stiffness equivalent to normal 
median lung stiffness levels even in the presence of 10% FBS 
but were detected with increasing frequency as substrate stiff-
ness increased (Fig. 2 D and Fig. S3 A). In contrast, serum   JCB • VOLUME 190 • NUMBER 4 • 2010   696
Figure 2.  Fibroblasts preferentially accumulate across stiffness gradient. (A) Human lung fibroblasts stained with phalloidin (red) to visualize F-actin and 
Hoechst 33342 (blue) to visualize nuclei. Cells attach uniformly across the stiffness gradient 4 h after seeding. After 120 h, fibroblasts accumulate prefer-
entially to stiffest region, and cell morphology transitions from round to spread. Panorama images were generated by imaging the entire gel width along 
the stiffness gradient and then tiling five to seven adjacent pictures. Arrowheads below the image indicate stitching positions. (B) Cell density is constant 
across the gradient after 4 h, but by 120 h, cells dramatically accumulate at stiffness >3 kPa and are lost below this stiffness level (note logarithmic scale). 
Density values are normalized to the global mean at 4 h. (C) Serum but not TGF-1 is required for stiffness-dependent cell accumulation. Serial dilutions 
of serum gradually attenuate the stiffness-dependent accumulation behavior (black, 10% FBS; blue, 1% FBS; green, 0.1% FBS; red, 0% FBS). 2 ng/ml 
exogenous TGF-1 shows little effect on cell density (open symbols and dotted lines) at any serum concentration. (B and C) Dashed lines indicate that cell 
density values are normalized to the global average obtained at 4 h. (D) Quantification of substrate stiffness effects on fibroblast apoptosis (blue indicates 
percentage of cells exhibiting caspase 3/7 activity after 24-h serum deprivation) and proliferation (red indicates percentage of nuclei positive for BrdU 
incorporation in 10% FBS). Standard deviation is from three independent experiments. (E) In panels B–D, colored triangles along the x axis are used to 
indicate the interquartile and median stiffness values of lung parenchyma from saline (cyan)- or bleomycin (red)-treated mice. (F) Fibroblast migration speed 
and persistence vary along substrate stiffness as measured with time-lapse video microscopy. Error bars indicate SD from 12 cells for each condition from 
two independent experiments. (G) Fibroblast migration tracks on stiffness gradient gels obtained from time-lapse video microscopy. Digital images were 
taken every 2 min for a total of 5 h per experiment. Each wind rose plot shows centroid tracks from 7–10 representative cells from each indicated stiffness 
region, with the initial position of each track superimposed at a common origin. Bars: (A) 500 µm; (G) 50 µm.697 Matrix stiffening amplifies fibrosis • Liu et al.
conditions spanning 100–25,600 Pa in fourfold increments. 
Cells grown from three independent human donors were used, 
and we focused our attention on genes with cross-donor rank 
correlation among stiffness conditions of >0.4, limiting analysis 
to the 2,462 probes (representing 1,829 unique genes) expressed 
in a consistent fashion among donors. We further restricted our 
attention to genes with a minimum within-donor coefficient of 
variation (of their exponentiated, base 2, robust multichip aver-
age [RMA] signal) across stiffness conditions of ≥0.2, resulting 
in a selection of 192 probes (150 of which have a gene assign-
ment), representing 124 unique genes which we classified as   
responsive to alterations in stiffness across all three donors.   
Hierarchical clustering based on linear correlation across the 
three donors identified two major clusters of genes, those whose 
expression generally increased with stiffness (Fig. S4 A) and 
those that decreased (Fig. S4 C) with increasing stiffness.
Ontological analysis of the cluster of genes increasing 
with stiffness identified highly significant enrichment for mito-
sis and microtubule motor activity (Fig. S4 B), which is consis-
tent  with  our  prior  measurement  of  enhanced  cell  division 
across increasing matrix stiffness (Fig. 2 D). A similar analysis 
low as 0.5 kPa (Fig. 3 A) and increased expression across the   
entire stiffness gradient (Fig. 3 B). However, the positive rela-
tionship between stiffness and procollagen I expression was 
maintained across the pathophysiological stiffness range even in 
the presence of supplemental TGF-1. This finding demonstrates 
cooperative enhancement of matrix synthesis through the action 
of soluble and mechanical signals and echoes previous examples 
of cooperative interactions between soluble and mechanical sig-
nals in myofibroblast activation (Arora et al., 1999; Goffin et al., 
2006). Together, these results demonstrate that physiological   
levels of lung tissue stiffness act as a powerful brake on procolla-
gen I synthesis but that either exogenous TGF- or matrix stiffen-
ing alone can overcome this physiological brake, with enhanced 
augmentation of matrix synthesis when both stimuli are present.
Stiffness-dependent fibroblast  
gene expression
To more rigorously test the assertion that increasing stiffness 
promotes expression of a fibrogenic cellular program, we per-
formed a microarray analysis of RNA harvested from normal 
human lung fibroblasts (NHLFs) grown on five discrete stiffness 
Figure 3.  Collagen synthesis increases across stiffness gradient. (A) Gradual increase of procollagen I protein expression in cells along the stiffness 
gradient. Nuclei are counterstained with Hoechst 33342 (blue). 2 ng/ml exogenous TGF-1 shifts procollagen I protein expression to lower stiffness and 
enhances expression on stiffer substrate regions (10% FBS). Bar, 100 µm. (B) Quantification of substrate stiffness effects on procollagen I protein expression 
in the presence (open symbols) and absence (closed symbols) of 2 ng/ml exogenous TGF-1 for cells grown in 10% FBS. (C) Expression of COL1A1 and 
COL3A1 transcripts increase with substrate stiffness, whereas MMP1 transcripts decrease with increasing stiffness for cells grown in 0.1% FBS. The dashed 
line indicates that the gene expression values are normalized to the values from the softest substrate. Error bars indicate SD from four replicate samples   
from one representative experiment. (D) Net collagen secretion per cell from fibroblasts grown on discrete stiffness gels over 72 h, cells grown in 1% FBS. 
*, P < 0.05 compared with 0.1 kPa. (B and D) Error bars indicate SD from two independent experiments. (B–D) Colored triangles along the x axis are used 
to indicate the interquartile and median stiffness values of lung parenchyma from saline (cyan)- or bleomycin (red)-treated mice.JCB • VOLUME 190 • NUMBER 4 • 2010   698
Because fibroblasts interacting with matrices of increas-
ing stiffness have been shown to alter activation of local matrix-
incorporated TGF- (Wipff et al., 2007), we sought to compare 
stiffness response genes to the transcriptional changes evoked 
by treatment with exogenous TGF-. We analyzed a previously 
published dataset reporting TGF-1–responsive genes in NHLFs 
(Kapoun et al., 2006), identifying 1,176 unique genes respon-
sive to this stimulus. Although there are subtle differences in 
culture conditions and passage number that should be noted in 
comparing our results with the TGF-–responsive gene list, of 
124 stiffness-responsive genes, only 33 genes were identified   
as also responsive to TGF-1 (Fig. S4). Strikingly, among these 
33 genes, expression levels of 18 were driven in opposite direc-
tions by the two stimuli (e.g., increasing with stiffness and de-
creasing with TGF-). This comparative analysis strongly 
suggests that the response to substrate stiffness identified in our 
microarray analysis is largely independent from a TGF-–driven 
transcriptional program.
Matrix stiffness promotes fibrogenesis 
through COX-2 suppression
One intriguing candidate gene that emerged from the micro-
array analysis was PTGS2 (Fig. 4 C), which encodes the COX-2 
enzyme. The COX enzymes convert arachidonic acid into pros-
taglandin H2, which is further processed into various prosta-
glandins, including PGE2. Notably, PGE2 is the most abundant 
of the subcluster of genes most prominently attenuated with   
increasing stiffness (Fig. 4 A) identified negative regulation of 
proliferation as a highly enriched ontology, as well as several 
functional annotations related to propeptide activation and pro-
teolytic activity in the extracellular space (Fig. 4 B). These on-
tologies were conspicuous for their inclusion of gene members 
MMP3, MMP10, and cathepsin K (CTSK), all of which are   
proteolytic for matrix proteins, including gelatin and fibrillar 
collagens. CTSK in particular has been shown to play a key role 
in protecting against lung fibrosis (Bühling et al., 2004). The 
microarray analysis also confirmed the changes in COL1A1 and 
MMP1 noted previously (Fig. 3 C), although the changes were 
modest relative to the strongest signals emerging from the   
microarray analysis (Fig. 4 C). Analysis by quantitative PCR 
(qPCR) confirmed the changes in transcript levels for MMP10, 
MMP3, and CTSK, along with PTGS2 across stiffness condi-
tions (Fig. 4 C). Collectively, these data suggest that matrix 
stiffening drives a broad gene expression program in support of 
fibroblast proliferation and selective but coordinated suppres-
sion of genes encoding collagen-degrading enzymes. Coupled 
with our demonstration that stiffness enhances procollagen syn-
thesis and suppresses MMP1 expression (Figs. 3 and 4), our 
findings are consistent with a potentially devastating adverse 
feedback loop in which progressive matrix stiffening begets   
enhanced matrix deposition and decreased matrix degradation 
by fibroblasts, promoting self-sustaining fibrosis.
Figure 4.  Stiffness drives coordinated expression of a fibro-
genic gene program. (A) Gene expression cluster of down-
regulated  transcripts  in  response  to  increasing  substrate 
stiffness from NHLFs (0.1% FBS). Each row displays relative 
expression levels from three donors for each gene, which has 
a minimum coefficient variance of 0.2 per donor. Columns 
within  each  donor  represent  gene  expression  for  stiffness   
effect at 0.1, 0.4, 1.6, 6.4, and 25.6 kPa. Genes are listed 
with their EntrezID, followed by their symbols according to 
the HUGO nomenclature. Hierarchical clustering is based on 
linear correlation across the three donors. (B) Top four annota-
tion clusters from functional annotation clustering analysis of 
genes in A. Corresponding genes within each annotation clus-
ter are marked with the same color next to the gene name in A.   
(C)  Selected  stiffness-regulated  gene  expression  from  array 
analysis. In panels with both solid and dashed lines, dashed 
lines represent array values averaged from three donors, and 
solid lines represent replicate analysis by real time qPCR using 
cells from donor 1. Data shown are means relative to the val-
ues at the stiffness 0.1 kPa. The final panel shows microarray 
data from three donors for PTGS1 and prostanoid receptors 
PTGER1–4. Error bars on dashed lines indicate SD from three 
donors; error bars on solid lines indicate SD from three inde-
pendent experiments using cells from donor 1.699 Matrix stiffening amplifies fibrosis • Liu et al.
receptor (Choung et al., 1998; Huang et al., 2007). We con-
firmed that suppression of PGE2 levels was a necessary step in 
stiffness-induced fibroblast accumulation by treating with ex-
ogenous PGE2 (Fig. 5 B) or the EP2 receptor agonist butaprost 
(EC50 5 µM; Fig. 5 C). Both treatments largely equilibrated   
fibroblast spatial density across a range of discrete matrix stiff-
ness conditions from 100 to 25,600 Pa in a dose-dependent 
fashion. Interestingly, suppression of endogenous COX-2 activ-
ity with NS-398 had little effect on fibroblast accumulation and 
was unable by itself to significantly enable proliferation on 
physiological stiffness conditions (Fig. 5 D). Thus, suppression 
of COX-2 and PGE2 alone, in the absence of increased matrix 
stiffness, is insufficient to engage fibroproliferation, indicating 
a dominant role for stiffness in holding this process in check.
We found similar effects of COX-2 and PGE2 on procolla-
gen synthesis across discrete matrix stiffness conditions. Exoge-
nous PGE2 (not depicted) and treatment with butaprost were both 
able to suppress stiffness-induced increases in procollagen ex-
pression, whereas NS-398 alone was unable to engage substantial 
prostaglandin in the airways, is present at high concentrations in 
healthy lungs, and is the predominant prostaglandin product of 
alveolar epithelial cells and lung fibroblasts (Ozaki et al., 1987; 
Huang and Peters-Golden, 2008). We confirmed that increasing 
matrix stiffness dramatically attenuates PTGS2 expression by 
qPCR (>80% reduction; Fig. 4 C), and extended this to show 
greatly diminished autocrine levels of PGE2 present in the 
supernatants of cultured fibroblasts on matrices of increasing 
stiffness (Fig. 5 A). The PGE2 levels were largely dependent on 
COX-2 activity, as selective inhibition of COX-2 with NS-398 
(IC50 for COX-2 is 1.8 µM and for COX-1 is 75 µM) reduced 
soluble PGE2 levels by 90–100% at low stiffness. We did not 
observe stiffness-dependent changes in expression of either 
COX-1 (PTGS1) or prostanoid receptor (PTGER1–4) levels 
(Fig. 4 C), further confirming that suppression of COX-2 ex-
pression was the dominant factor in the attenuation of PGE2 
levels with increasing stiffness.
PGE2 has been shown to suppress fibroblast proliferation 
and collagen synthesis by signaling through the EP2 prostanoid 
Figure 5.  PGE2 regulates fibroblast responses to increasing stiffness. (A) Relative PGE2 levels in NHLF cell culture supernatants with and without selective 
COX-2 inhibitor (NS-398). (B–D) NHLF accumulation in discrete stiffness wells (1% FBS) and modification by exogenous PGE2, EP2 agonist (butaprost; 
Buta), and COX-2 inhibitor (NS-398), respectively. (E) Immunostaining for procollagen I in NHLFs (1% FBS). EP2 agonist (5 µM butaprost) abrogates the 
stiffness effect on procollagen I expression, whereas COX-2 selective inhibitor (3 µM NS-398) is unable to augment procollagen I expression at low stiffness. 
Bar, 50 µm. (F) Relative mRNA levels for COL1A1, assessed by qPCR, on 0.1 and 6.4 kPa substrates (0.1% FBS) with and without 5 µM butaprost or 3 µM 
NS-398. (A–D and F) Error bars indicate SD from three independent experiments for each panel. (G) COX-2 (PTGS2) mRNA levels decrease across stiff-
ness, as measured by qPCR, in A549 human lung epithelial cells, primary human dermal, synovial and lung (NHLF) fibroblasts, and airway smooth muscle 
(ASM) cells, as well as CCL-151 and IMR90 lung fibroblast cell lines (0.1% FBS). (A–D and G) Colored triangles along the x axis are used to indicate the 
interquartile and median stiffness values of lung parenchyma from saline (cyan)- or bleomycin (red)-treated mice.JCB • VOLUME 190 • NUMBER 4 • 2010   700
Figure 6.  ROCK and PGE2 exert mutually antagonistic effects on fibroblasts. (A) Increasing stiffness enhances organization of filamentous F-actin cyto-
skeleton (red) and triggers formation of paxillin-positive focal adhesions (green). The effect of stiffness on formation of these cellular structures is reversed 
with 30 ng/ml exogenous PGE2, in a fashion identical to treatment with 33 µM of the ROCK inhibitor Y27632 (1% FBS). (B) Increasing stiffness drives 
expression and assembly of -SMA (green) into F-actin stress fibers (red). The effect of stiffness on -SMA is reversed with 30 ng/ml exogenous PGE2, in 
a fashion identical to treatment with 33 µM of the ROCK inhibitor Y27632 (1% FBS). (C) 33 µM Y27632 increases expression of COX-2 (PTGS2) mRNA 
across matrix stiffness conditions (0.1% FBS), relative to untreated cells (CTRL). Error bars indicate SD from three replicate samples from one representative 
experiment. (D) 33 µM Y27632 equilibrates endogenous PGE2 levels across matrix stiffness conditions (0.1% FBS), relative to untreated cells (CTRL). Error 
bars indicate SD from three independent experiments. (C and D) Colored triangles along the x axis are used to indicate the interquartile and median stiff-
ness values of lung parenchyma from saline (cyan)- or bleomycin (red)-treated mice. (E) Results are consistent with mutually antagonistic and self-reinforcing 701 Matrix stiffening amplifies fibrosis • Liu et al.
promoting fibroblast activation (Fig. 6 E). Because these fibro-
blast states lead to self-reinforcing effects on matrix synthesis 
and degradation (Figs. 2–4), matrix stiffening and the accompa-
nying shift in balance between quiescence and activation repre-
sent a critical step toward self-sustaining fibrosis.
Discussion
With the use of AFM microindentation, we found that emerging 
fibrotic lesions in the murine model of bleomycin-induced   
fibrosis exhibit median stiffness sixfold higher than surrounding 
normal lung parenchyma. The increases in stiffness far exceed 
previous macroscale measurements of fibrotic stiffening of the 
lung (Ebihara et al., 2000), and their highly localized nature is 
consistent with the patchy nature of both the bleomycin model 
and human disease (Selman et al., 2001; Moore and Hogaboam, 
2008). Although prior work has established that fibroblast pro-
liferation  and  myofibroblast  differentiation  vary  with  matrix 
stiffness (Arora et al., 1999; Wang et al., 2000; Goffin et al., 2006; 
Li et al., 2007), our work shows for the first time that fibro-
blast proliferation and procollagen I synthesis are completely 
suppressed at the median stiffness of normal lung tissue, even in 
the presence of serum, suggesting a dominant role for normal 
lung compliance in maintaining the fibroblast quiescence typi-
cally observed in vivo but, notably, not in cell culture on rigid 
surfaces. Across the pathophysiological range identified in emerg-
ing fibrotic lesions, we observed that matrix stiffness progres-
sively activates fibroblasts to proliferate and for the first time 
documented a coordinated program of enhanced collagen syn-
thesis and suppression of transcripts encoding matrix-degrading   
proteases. Together, these findings establish that stiffness within the 
pathophysiological range exerts profound effects on the key as-
pects of fibroblast biology central to lung fibrosis. Based on these 
findings, we propose that an adverse feedback cycle of matrix 
stiffening, fibroblast proliferation, and net matrix synthesis un-
derlies the relentless progressive nature of severe lung fibrosis.
Our study identifies suppression of COX-2 expression and 
PGE2 synthesis as necessary elements in the fibroblast prolifer-
ative and matrix synthetic responses to increasing matrix stiff-
ness. Although various eicosanoids have been demonstrated to 
play both positive and negative roles in animal models of fibro-
sis (Lovgren et al., 2006; Oga et al., 2009), COX-2 and PGE2 
levels are known to be reduced in the lungs of patients with fibro-
sis relative to healthy individuals (Borok et al., 1991; Xaubet   
et al., 2004), and fibroblasts isolated from fibrotic lungs are 
known to be deficient in PGE2 synthesis (Wilborn et al., 1995; 
Vancheri et al., 2000; Keerthisingam et al., 2001). Our data pro-
vide the first physiological explanation for these deficiencies. 
Exogenous PGE2 is well appreciated to suppress fibroblast pro-
liferation and activation (Lama et al., 2002; Huang et al., 2007; 
Sandulache et al., 2007; Thomas et al., 2007; Weinberg et al., 
procollagen synthesis on physiological stiffness substrates (Fig. 5 E 
and Fig. S5). These results were largely mirrored at the message 
level by changes in COL1A1 (Fig. 5 F).
Although the suppressive effects of COX-2 and PGE2 on 
fibrogenesis and fibroproliferation are best known in the context 
of lung fibrosis (Vancheri et al., 2004; Huang and Peters-Golden, 
2008), limited evidence also implicates this axis in fibrogenesis 
in other tissues and contexts (Hui et al., 2006; Sandulache et al., 
2007; Liu et al., 2009). Therefore, we tested whether the stiffness-
dependent suppression of PTGS2 was a feature common to 
multiple cell types. We found that increasing matrix stiffness 
suppressed PTSG2 expression to varying degrees in primary 
human dermal fibroblasts, synovial fibroblasts, airway smooth 
muscle  cells,  and  the A549  human  lung  epithelial  cell  line, 
along with similar changes in NHLF, CCL-151, and IMR90   
human lung fibroblasts (Fig. 5 G). These findings suggest that 
stiffness-dependent suppression of COX-2 expression and pros-
taglandin signaling may have potentially broad relevance.
Numerous studies link the Rho/ROCK pathway to matrix 
stiffness responses (Paszek et al., 2005; Peyton and Putnam, 
2005; Assoian and Klein, 2008), although none have examined 
the interrelationship of stiffness, Rho/ROCK, and prostaglandin 
signaling. We observed that increasing matrix stiffness triggers 
dramatic changes in the organization of focal adhesions and actin   
stress fibers (Fig. 6 A), along with -SMA staining (Fig. 6 B), 
which is consistent with prior work (Yeung et al., 2005; Goffin 
et al., 2006; Li et al., 2007). Strikingly, the addition of exoge-
nous PGE2 had little effect on these structures at low stiffness 
but dramatically attenuated their presence at high stiffness (Fig. 6, 
A and B), resulting in indistinguishable cell morphologies,   
actin cytoskeletal organization, and adhesion structures between 
the two stiffness extremes in the presence of exogenous PGE2. 
The  morphological  and  cytoskeletal  responses  to  exogenous 
PGE2 were sustained for up to 24 h (unpublished data) and were 
comparable in scope with those induced by blocking ROCK activ-
ity with Y27632, suggesting an antagonistic relationship be-
tween PGE2 and ROCK.
We also found that blocking ROCK with Y27632 increased 
COX-2 expression across the entire range of matrix stiffness 
tested (Fig. 6 C) and largely equilibrated the autocrine levels of 
PGE2 present across matrix stiffness conditions (Fig. 6 D). Thus, 
endogenous ROCK activity suppresses COX-2 expression and 
PGE2 synthesis in lung fibroblasts, whereas exogenous PGE2 
mimics ROCK inhibition. Collectively, these findings demon-
strate that Rho/ROCK and COX-2/PGE2 signaling exert mutu-
ally antagonistic effects on fibroblast morphology, cytoskeletal 
structure, and focal adhesions. Our results suggest that the rela-
tive balance between these antagonistic pathways defines two   
fibroblast phenotypes: active (high Rho and low COX-2) and 
quiescent (low Rho and high COX-2), with normal lung stiffness 
maintaining the quiescent phenotype and matrix stiffening   
effects of Rho/ROCK and COX-2/PGE2 signaling in fibroblasts. Under normal conditions, autocrine PGE2 and PGE2 contributions from surrounding cells, 
coupled with the compliant nature of the normal matrix, maintain fibroblasts in a quiescent state. Increasing matrix stiffness suppresses endogenous COX-2 
and shifts fibroblasts into an activated state. Subsequent matrix synthesis generates positive feedback on matrix synthesis, leading to persistent fibroblast 
activation and progressive matrix stiffening. Bars, 50 µm.
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relationship sets up two feedback loops, both self-reinforcing, 
that drive fibroblasts to one of two extremes, activated (high 
Rho and low COX-2) or quiescent (low Rho and high COX-2). 
We speculate that in the lung, abundant PGE2, produced by 
fibroblasts and surrounding epithelial cells (Ozaki et al., 1987; 
Wilborn et al., 1995; Lama et al., 2002), normally maintains the 
quiescent phenotype but that lung injury and matrix stiffening 
act in part through effects on PGE2 levels to tilt the balance to-
ward persistent, self-sustaining fibroblast activation (Fig. 6 D). 
Although we have not pinpointed the precise molecular inter-
actions between Rho/ROCK and COX-2/PGE2 in these experi-
ments, PGE2 is known to signal through cAMP in lung fibroblasts 
(Choung et al., 1998; Huang et al., 2007), and cAMP and down-
stream protein kinase A have been shown to both inactivate Rho 
and lead to cofilin-mediated actin depolymerization in multiple 
cell types (Dong et al., 1998; Lang et al., 1996; Murthy et al., 
2003; Goeckeler and Wysolmerski, 2005), which is consistent 
with our observations.
How increasing matrix stiffness regulates expression of 
COX-2 is unknown. Recent findings indicate that diminished 
expression of COX-2 in fibroblasts isolated from fibrotic lungs 
is caused by defective histone acetylation in the COX-2 pro-
moter (Coward et al., 2009). Epigenetic regulation of COX-2 is 
consistent with the observations that certain stimuli can provoke 
long-lasting changes in COX-2 expression that persist through 
multiple cell divisions (Korn, 1983) and could explain how de-
ficiencies in PGE2 secretion remain stable in serially passaged 
cells in culture (Wilborn et al., 1995; Vancheri et al., 2000; 
Keerthisingam et al., 2001). Although not yet well established, 
early evidence suggests that changes in matrix stiffness and cell 
shape do indeed regulate global levels of histone acetylation   
(Le Beyec et al., 2007). Further studies will be needed to elucidate 
the molecular links connecting matrix stiffness to gene expres-
sion and to test the role that epigenetic regulation plays in stiffness-
dependent cellular behaviors.
In conclusion, we demonstrate for the first time that the 
median stiffness of normal lung tissue strongly inhibits the fibro-
blast  functions  at  the  core  of  fibrosis  and  elucidate  a  novel 
mechanism linking matrix stiffening to fibroblast activation in 
part through suppression of an endogenous COX-2/PGE2 inhib-
itory pathway. Our data imply that fibrotic stiffening of a critical 
mass and extent, once established, is sufficient to generate a 
self-sustaining fibrotic process by virtue of its activation of fibro-
blasts, suppression of autoinhibitory COX-2/PGE2, and subsequent 
feedback amplification of stiffness through net matrix synthesis. 
Importantly, our results imply that fibroblasts within a stiffened 
fibrotic lesion are primed to engage in further fibrogenic activities. 
The instability inherent in the presence of a mechanobiological 
profibrotic feedback loop could help to explain the variable 
course of the disease and rapid declines in lung function seen in 
exacerbations of lung fibrosis (Martinez et al., 2005; Collard   
et al., 2007). Based on the fact that similar stiffness levels and 
cellular behaviors are observed during fibrogenesis in other soft 
tissues (Georges et al., 2007; Li et al., 2007; Wells, 2008), we 
propose that the mechanobiological feedback loop detailed in 
this study may represent a common feature of progressive fibro-
sis. Improved recognition of how constraints are broken to   
2009) and limit experimental lung fibrosis (Failla et al., 2009), 
but our data expand on this by demonstrating that endogenous 
PGE2 is secreted at high levels by fibroblasts growing on physi-
ological stiffness matrices, and this capacity is gradually lost as 
matrix stiffness increases. However, notably, on soft substrates, 
pharmacological treatment to suppress COX-2 activity alone 
was insufficient to engage fibroblast proliferation and collagen 
synthesis, demonstrating that redundant mechanisms protect 
against spontaneous fibroblast activation when cells are resident 
in an environment as compliant as the normal lung. These find-
ings are supported by animal models in which genetic deletion 
of COX-2 alone was insufficient to initiate fibrosis in the lung 
but did increase susceptibility to and severity of experimentally 
induced lung fibrosis (Keerthisingam et al., 2001; Bonner et al., 
2002; Hodges et al., 2004). Collectively, our findings document 
a double layer of protection against fibrosis in the lung through 
the innate suppressive effects of the lung’s mechanical compliance, 
coupled with the abundant PGE2 production it engenders.
TGF- is widely acknowledged to play a key role in driv-
ing fibrogenesis through its effects on activation of fibroblasts to 
myofibroblasts and stimulation of matrix synthesis (Tomasek   
et al., 2002). Recent work indicates that fibroblasts grown for sev-
eral days on matrices of varying stiffness activate matrix-bound 
TGF- in a stiffness-dependent fashion (Wipff et al., 2007). We 
were surprised to find through microarray analysis that the early 
(48 h) fibroblast genomic response to stiffness is both supportive 
of proliferation and suppressive of collagen degradation but 
largely diverges from responses driven by TGF-. Nowhere was 
this divergence more clear than in the case of COX-2. Although 
we found that increasing matrix stiffness suppressed COX-2 ex-
pression and downstream synthesis of PGE2, TGF- has been 
shown  to  stimulate  COX-2  expression  and  PGE2  production 
(Diaz et al., 1989; McAnulty et al., 1995; Keerthisingam et al., 
2001; Kapoun et al., 2006). Because PGE2 acts to suppress 
TGF-–driven responses in fibroblasts (Kolodsick et al., 2003; 
Sandulache et al., 2007; Thomas et al., 2007), the COX-2/PGE2 
stimulation by TGF- is thought to dampen cellular responses to 
this fibrogenic cytokine and prevent overexuberant fibrotic reac-
tions. Our data raise the possibility that fibroblasts resident on 
stiff matrices experience enhanced responses to TGF- because 
of stiffness-dependent down-regulation of a usual brake on   
TGF- signaling. This may account, in part, for the emergence 
of TGF- responses that we and others (Arora et al., 1999;   
Goffin et al., 2006) observe on matrices of increasing stiffness.
How variations in matrix stiffness are transduced by cells 
remains an area of intense investigation. Several important mo-
lecular players have emerged, including integrins (Paszek et al., 
2005; Friedland et al., 2009), focal adhesion proteins such as 
FAK (Pelham and Wang, 1997; Paszek et al., 2005; Assoian and 
Klein, 2008), and cytoskeletal tension driven by the action of 
myosin II (Engler et al., 2006). Our results indicate that an   
antagonistic relationship between ROCK and COX-2 activities 
shapes fibroblast responses to matrix stiffness, wherein ROCK 
suppresses COX-2 expression and activity, whereas the COX-2 
downstream product PGE2 acts in a fashion similar to a ROCK 
inhibitor in disassembling the focal adhesions and stress fibers 
that form as matrix stiffness increases. This mutually antagonistic 703 Matrix stiffening amplifies fibrosis • Liu et al.
Cell culture and cell density measurements
Lung fibroblasts (CCL-151) were cultured in Kaighn’s Modification of Ham’s 
F12 medium (F12K) supplemented with 10% FBS (Lonza), 100 U/ml penicil-
lin, and 100 µg/ml streptomycin. Gradient stiffness gels were seeded at   
50 cells/mm
2 in 6-well plates. After 4 h, gels were gently washed with fresh 
medium and then moved into new wells. Cells were cultured for 5 d before 
fixation  for  immunostaining.  For  TGF-1  treatment,  2  ng/ml  TGF-1  was 
added at day 2 and day 4. To generate panorama images, the entire gel 
width was imaged along the stiffness gradient by tiling 5–7 adjacent pictures. 
Cell density was determined by counting nuclei numbers on fluorescent images 
with MetaMorph 6.1. Density values were normalized to the global mean 
value from 4-h attachment. NHLFs were seeded at a density of 50 cell/mm
2 in   
96-well plates containing gels with five individual discrete stiffnesses: 0.1, 
0.4, 1.6, 6.4, and 25.6 kPa. Cells were cultured with F12K containing 1% 
FBS at 37°C and 5% CO2. After 48 h, cell density was determined using   
CyQuant NF Cell Proliferation Assay (Invitrogen). Density values were nor-
malized to the global mean value from 4-h attachment. For drug treatments, 
PGE2, butaprost, or NS-398 was added after 4-h initial attachment. In gen-
eral, NHLFs or CCL-151 cells were cultured in 0.1% FBS for microarray and 
qPCR analysis to minimize differences in transcript levels caused by varia-
tions in proliferation and cell cycle progression. NHLFs were cultured in 1% 
FBS for proliferation, procollagen expression, PGE2, and collagen secretion 
analysis; CCL-151 cells grew more slowly and were cultured in 10% FBS for 
proliferation and procollagen expression analyses.
Proliferation and apoptosis assays
Fibroblasts were cultured on stiffness gradients for 4 d and then exposed 
to 50 µM BrdU for 24 h, fixed, permeabilized with 0.5% Triton X-100, 
treated with 4N hydrochloric acid for 15 min, and then neutralized with 
0.1 M sodium borate, pH 8.5, for 20 min. Cells were then stained with 
anti-BrdU antibody (Alexa Fluor 546 mAb IgG1; Invitrogen) to identify 
replicating cells and with Hoechst 33342 to determine total cell number. 
For measurement of apoptosis, fibroblasts cultured on stiffness gradients 
for 4 d were serum-starved for 24 h and then stained with Image-iT Live 
green Caspase Detection kit (Invitrogen) to detect caspase 3/7 activity.
Migration assay
Cell migration data were generated using a time-lapse videomicroscopy 
system consisting of an inverted microscope (Leica) with 10× phase- 
contrast objective, charge-coupled device camera, and automated data ac-
quisition software (MetaMorph 6.1). A temperature and CO2 control system 
was used for the maintenance of cell viability. Cells grown on stiffness gra-
dients for 24 h were imaged every 2 min for 5 h. Cell xy-centroids and dis-
placements were determined using MetaMorph 6.1 cell tracking module. 
Only cells that did not divide, touch other cells, or leave the image field 
during the experiment were used for data analysis. Single cell speed was 
derived by dividing total cell path length by the total time of migration. Sin-
gle cell persistence was derived from nonlinear least-squares regression   
using individual cell speed and mean-squared cell displacement as described 
previously (Harms et al., 2005).
Discrete stiffness gel preparation
Glass-bottom 96-well plates (Matrical) were treated with a 0.4% aqueous so-
lution of g-methacryloxypropyltrimethoxysilane (Acros Organics). Solutions 
containing  0.075%  ammonium  persulfate,  0.15%  tetramethylethylenedi-
amine, and variable ratios of acrylamide/bisacrylamide (Bio-Rad Laborato-
ries) were delivered into the well plate. A 96-pin block with affixed, 
hydrophobic glass squares corresponding to the diameter of the wells was in-
serted, sandwiching the polymerization solutions between two glass surfaces. 
Gel thickness was controlled by placing 100-µm-thick spacers in the corner 
wells. After polymerization, the gel surface was derivatized with heterobifunc-
tional cross-linker Sulfo-SANPAH (Thermo Fisher Scientific; Pelham and Wang, 
1997). Monomeric collagen (PureCol) diluted in PBS at 100 µg/ml was   
delivered to each well and incubated for 4 h at room temperature. The well 
plate was rinsed in PBS and UV-sterilized before cell seeding.
Microarray analysis
NHLFs  from  three  independent  donors  were  seeded  at  a  density  of   
50 cell/mm
2 in 96-well plates containing gels with five individual discrete stiff-
nesses: 0.1, 0.4, 1.6, 6.4, and 25.6 kPa. Cells were allowed to attach to 
the gels in serum-free F12K media for 4 h and incubated at 37°C and 5% 
CO2. Media was then replaced with F12K containing 0.1% FBS to mini-
mize differences in transcript levels caused by variations in proliferation 
and cell cycle progression. After 48 h, cells were lysed with 50 µl RNA   
lysis buffer per well (QIAGEN). Replicate stiffness wells were pooled, and 
RNA was isolated (RNeasy mini kit; QIAGEN) and quantified with RiboGreen 
engage this feedback loop may prove critical for developing 
new prevention or early intervention strategies, whereas further 
elucidation of the mechanisms linking matrix stiffness to on-
going fibroblast activation may lead to new therapeutic opportuni-
ties for the treatment of progressive fibrosis.
Materials and methods
Animals and bleomycin administration
C57BL/6 mice (The National Cancer Institute Animal Production Program) 
were instilled intratracheally with 0.05 U bleomycin (Gensia Sicor Pharma-
ceuticals Inc.) in 50 µl sterile saline or with 50 µl sterile saline for control 
mice, with lung tissue harvested 14 d later (Tager et al., 2008). All experi-
ments were performed in accordance with National Institutes of Health 
guidelines and protocols approved by the Massachusetts General Hospital 
Subcommittee on Research Animal Care, and all mice were maintained in 
a specific pathogen-free environment certified by the American Association 
for Accreditation of Laboratory Animal Care.
Lung parenchyma strip preparation and elastomapping
Mouse lung parenchyma strips were prepared by inflating lungs with 2% 
low gel point agarose at 37°C (50 ml/kg body weight) followed by cooling 
to 4°C. Tissue strips of 5 × 5 mm in length and width and 400 µm in thick-
ness were cut with a razor blade from subpleural regions, excluding larger 
airways, and then washed in PBS at 37°C to remove the agarose (Bergner 
and Sanderson, 2003). The samples were placed on poly-l-lysine–coated 
coverslips. Samples were mechanically characterized using an atomic force 
microscope (MFP-3D; Asylum Research) by performing microindentation   
using a sphere-tipped probe (Novascan) with a diameter of 5 µm and a nomi-
nal spring constant of 60 pN/nm. The cantilever spring constant was   
further confirmed by the thermal fluctuation method (Thundat et al., 1994). 
The AFM system was calibrated by following the manufacturer’s instruction 
before each indentation measurement. Force-indentation profiles were ac-
quired at an indentation rate of 20 µm/s separated by 5 µm spatially in a 
16 × 16 sample grid covering an 80 × 80–µm area. Shear modulus at 
each point on the grid was calculated from fitting force-indentation data   
using a Hertz sphere model (Richert et al., 2004), and resulting shear modu-
lus data were plotted in contour maps. For lung tissue, a Poisson’s ratio of 
0.4 (Butler et al., 1986) was used to convert elastic modulus (E) to shear 
modulus (G), using the relationship E = 2 × (1 + ) × G.
Immunofluorescence imaging
Lung tissue strips were immunostained after blocking with 5% goat serum 
without permeabilization. Human lung fibroblasts (CCL-151; American 
Type Culture Collection) cultured on stiffness gradients for 5 d or NHLFs 
(Lonza) cultured in 96-well plates containing individual discrete stiffness 
gels for 2 d were immunostained after fixation, permeabilization, and 
blocking with 5% goat serum. Primary antibodies used were obtained 
from Sigma-Aldrich (collagen I mAb COL-1, Paxillin mAb PXC-10, -SMA 
mAb, 1A4) and Fitzgerald (ProCollagen I mAb PCIDG10). Secondary 
antibodies were obtained from Invitrogen (Alexa Fluor 488 or 546 goat 
anti–mouse IgG2a and Alexa Fluor 488 or 546 goat anti–mouse IgG1) 
and Polysciences (goat anti–mouse IgG–coated fluorescent yellow-green 
1.0-µm microspheres). F-actin and nuclei were stained with Alexa Fluor 
546–phalloidin and Hoechst 33342 (Invitrogen), respectively. Fluores-
cence  images  were  obtained  with  a  fluorescent  microscope  (TE300; 
Nikon). The final image contrast was adjusted with MetaMorph 6.1 
(MDS Analytical Technologies) by setting the background to the fluores-
cence intensity level of the samples in the corresponding secondary   
antibody-only control images. Panorama images were assembled with 
Photoshop 6.0 (Adobe).
Stiffness gradient substrate preparation
An aqueous solution containing 12% acrylamide, 0.3% bisacrylamide, 
and 3.0 mg/ml Irgacure 2959 (photoinitiator; Ciba) was pipetted between 
two 22 × 22–mm coverslips and polymerized by exposure to UV light   
(365 nm; 7.0 mW/cm
2) for 6.5 min at 30°C. Linear stiffness gradients 
were obtained by modulating the intensity of UV light exposure through a 
filter mask with a clear to 100% gradient in opacity (Wong et al., 2003). 
Stiffness was measured by AFM and converted from elastic modulus to 
shear modulus assuming a Poisson’s ratio of 0.3 (Li et al., 1993). The conver-
sion from shear to elastic (Young’s) modulus is thus E = 2.6 × G.JCB • VOLUME 190 • NUMBER 4 • 2010   704
stiffness system and demonstrates uniform collagen density across the stiff-
ness gradient. Fig. S3 contains panorama fluorescence micrographs show-
ing BrdU, caspase 3/7 activity, and procollagen staining across stiffness   
gradients. Fig. S4 provides complete hierarchical clustering of matrix stiffness- 
regulated genes, top over-represented ontological categories among these 
genes, and relative TGF- responsiveness of stiffness-regulated genes.   
Fig. S5 demonstrates the consistent effect of increasing stiffness on procolla-
gen I expression, attenuated by EP2 receptor agonist butaprost. Table S1 pro-
vides sequence information for qPCR primers. Online supplemental material is 
available at http://www.jcb.org/cgi/content/full/jcb.201004082/DC1.
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reagent (Invitrogen). RNA extracts were used to generate labeled cRNA 
and hybridized to GeneChip Human Gene 1.0 ST arrays according to the 
standard protocol (Affymetrix). The resulting raw CEL file data were pro-
cessed using standard RMA normalization into a numerical data matrix for 
subsequent  mathematical  analyses.  These  data  are  publicly  available   
at  the  National  Center  for  Biotechnology  Information  Gene  Expression   
Omnibus  (http://www.ncbi.nlm.nih.gov/geo/)  under  accession  num-
ber GSE22011. Gene expression analysis was limited to 2,462 probes 
with cross-donor rank correlation among stiffness conditions of >0.4. The 
analysis was further restricted to 192 probes (150 of which have a gene 
assignment) representing 124 unique genes with minimum within-donor 
coefficient of variation (of their exponentiated, base 2, RMA signal) across 
stiffness conditions of ≥0.2. Hierarchical clustering was performed on the 
selected 150 probes based on linear correlation across the three donors. 
Before hierarchical clustering, the stiffness expression signal profile of each 
gene was standardized to mean zero, variance one within each donor. 
Ontological analysis was conducted using DAVID functional annotation 
clustering tool (http://david.abcc.ncifcrf.gov/summary.jsp).
RNA analysis
Lung fibroblasts (CCL-151, NHLFs, and IMR90), normal human dermal   
fibroblasts, human airway smooth muscle cells, A549 lung epithelial cells, 
and human synovial fibroblasts were seeded at a density of 50 cells/mm
2 
in 96-well plates containing individual discrete stiffness gels. Synovial fibro-
blasts were prepared and cultured from discarded synovial tissues from 
rheumatoid arthritis patients (American College of Rheumatology criteria), 
obtained with approval of the Brigham and Women’s Hospital Institutional 
Review Board from synovectomy or joint replacement procedures (courtesy 
of Z. Gu and M. Brenner, Harvard Medical School and Brigham and Women’s   
Hospital, Boston, MA). All cells were allowed to attach to the gels in   
serum-free F12K media for 4 h and incubated at 37°C and 5% CO2. Media 
was then replaced with F12K containing 0.1% FBS. After 48 h, cells were 
lysed with 50 µl of RNA lysis buffer per well (QIAGEN). Replicate stiffness 
wells were pooled, and RNA was isolated (RNeasy mini kit) and quantified 
with RiboGreen reagent. 50 ng of each sample was primed with oligo (dT) 
and reverse transcribed into cDNA using Taqman reverse transcription   
reagents (Applied Biosystems) at 25°C for 10 min, 37°C for 60 min, and 
95°C for 5 min. Equivalent amounts of each cDNA sample were added to 
Power SYBR green PCR master mix (Applied Biosystems) containing 1 µM 
each of forward and reverse primer (Table S1) for mRNA amplification. 
Primers  were  designed  with  qPrimerDepot  (http://primerdepot.nci.nih 
.gov) and are intron overlapping. qPCR was performed by incubating at 
95°C for 10 min to activate AmpliTaq Gold DNA polymerase (Applied 
Biosystems) and then cycling 40 times at 95°C for 15 s and 60°C for   
1 min. Ct values within each experiment were normalized against GAPDH 
(glyceraldehyde 3-phosphate dehydrogenase), and mRNA levels were ex-
pressed relative to the softest substrate tested.
PGE2 assays
NHLFs were seeded at a density of 50 cells/mm
2 in 96-well plates contain-
ing individual discrete stiffness gels. Cells were cultured with F12K contain-
ing 1% FBS at 37°C and 5% CO2. After 48 h, cell culture media were 
collected,  and  the  PGE2  enzyme-linked  immunosorbent  assay  was  per-
formed  according  to  manufacturer’s  instructions  (Cayman  Chemicals). 
PGE2 concentrations were normalized to the corresponding cell numbers 
and then to the values at the lowest stiffness.
Soluble collagen assay
NHLFs were seeded at a density of 50 cell/mm
2 in 96-well plates contain-
ing gels with five individual discrete stiffnesses: 0.1, 0.4, 1.6, 6.4, and 
25.6 kPa. Cells were cultured with F12K containing 1% FBS at 37°C and 
5% CO2. After 72 h, cell culture media were collected, and the collagen 
concentration was measured using Sircol Soluble Collagen Assay kit ac-
cording to manufacturer’s instructions (Biocolor). Collagen concentrations 
were normalized to the corresponding cell numbers as measured with   
CyQuant Assay.
Statistical analysis
Results are expressed as means ± SD. Data were analyzed by nonparamet-
ric Mann-Whitney-Wilcoxon test or t test using the Prism statistical program 
(GraphPad Software, Inc.). P-values <0.05 were considered significant.   
Error bars depict SD.
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